Effect of high dose magnesium sulfate on inflammatory process in patients undergoing gastrointestinal cancer surgery

Investigation of the Impact of High-Dose Intravenous Magnesium Sulfate Administration on the Improvement of Symptoms Associated with Inflammation in Patients Undergoing Gastrointestinal Cancer Surgery at the Intensive Care Unit of Imam Khomeini Hospital, Tehran

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120216009045N7

Enrollment

Registered

2024-12-24

Start date

2024-11-30

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with gastrointestinal cancer undergoing surgery. Malignant neoplasms of digestive organs, gastrointestinal cancer,malignancy,

Interventions

Intervention 1: Intervention group: Patients in this group receive intravenous magnesium sulfate supplement 20% (30 ml+ 50 ml normal saline) Pasteur Institute Company at a dose of 6 grams once and the

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Gastrointestinal cancer patients after surgery are admitted to the intensive care unit.

Exclusion criteria

Exclusion criteria: Patients with severe organ failure, including acute renal failure, cardiac arrhythmia, and hepatic failure, as well as any contraindication to intravenous magnesium administration, such as low blood pressure.

Design outcomes

Primary

Measure	Time frame
C- reactive protein. Timepoint: Before intervnetion and 48 hours after intervention. Method of measurement: Auto Chemistry Analyzer kits.;Interleukin 6. Timepoint: Before intervnetion and 48 hours after intervention. Method of measurement: ELISA kit.;Tumor necrosis factor alpha. Timepoint: Before intervnetion and 48 hours after intervention. Method of measurement: ELISA kit.;Procalcitonin. Timepoint: Before intervnetion and 48 hours after intervention. Method of measurement: Auto Chemistry Analyzer kits.;Erythrocyte sedimentation rate. Timepoint: Before intervnetion and 48 hours after intervention. Method of measurement: Auto Chemistry Analyzer kits.;Interleukin 10. Timepoint: Before intervnetion and 48 hours after intervention. Method of measurement: ELISA kit.;Sequential Organ Failure Assessmen. Timepoint: Daily. Method of measurement: Questionnaire.;Acute Physiology and Chronic Health Evaluation (APACHE) score. Timepoint: First day of admission in intensive care unit. Method of measurement: Questionnaire.	—

Measure

Time frame

C- reactive protein. Timepoint: Before intervnetion and 48 hours after intervention. Method of measurement: Auto Chemistry Analyzer kits.;Interleukin 6. Timepoint: Before intervnetion and 48 hours after intervention. Method of measurement: ELISA kit.;Tumor necrosis factor alpha. Timepoint: Before intervnetion and 48 hours after intervention. Method of measurement: ELISA kit.;Procalcitonin. Timepoint: Before intervnetion and 48 hours after intervention. Method of measurement: Auto Chemistry Analyzer kits.;Erythrocyte sedimentation rate. Timepoint: Before intervnetion and 48 hours after intervention. Method of measurement: Auto Chemistry Analyzer kits.;Interleukin 10. Timepoint: Before intervnetion and 48 hours after intervention. Method of measurement: ELISA kit.;Sequential Organ Failure Assessmen. Timepoint: Daily. Method of measurement: Questionnaire.;Acute Physiology and Chronic Health Evaluation (APACHE) score. Timepoint: First day of admission in intensive care unit. Method of measurement: Questionnaire.

—

Secondary

Measure	Time frame
Intensive care stay time. Timepoint: Intensive care discharge time. Method of measurement: Questionnaire.;28 days mortality. Timepoint: 28 days after admition. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Taghi Beigmohamadi

Tehran University of Medical Sciences

mbage46@gmail.com+98 21 6119 2512

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026